Argenica Therapeutics (AGN) Investor presentation summary

Mission, vision, and impact

• Aims to commercialize neuroprotective treatments to minimize brain damage and optimize recovery after stroke and other neurological conditions.

• Seeks to redefine the standard of care for stroke by reducing brain injury and improving patient outcomes.

• Focuses on creating life-altering impact for millions suffering from neurological conditions.

Lead asset and clinical progress

• ARG-007 has shown efficacy signals in a Phase 2 stroke trial and is clinically advanced.

• Demonstrates multiple mechanisms of action across several neurological conditions.

• Supported by granted patents, strong IP, and over 25 peer-reviewed publications.

• Single dose of ARG-007 in severe TBI can move directly from preclinical to Phase 2 clinical trial.

Market opportunity and unmet need

• Stroke is targeted first due to high incidence and significant unmet need; 1.9 million brain cells die every minute during a stroke.

• Only 10% of stroke patients recover almost completely; current treatments reach a small fraction of patients.

• In Australia, ~45,000 strokes occur annually with AUD $5.5B in healthcare costs; in the US, ~795,000 strokes annually with costs projected to reach USD $423B by 2050.

• Thrombolytic drugs serve as a market comparable, but only 9% of acute ischaemic stroke patients are eligible.